Skip to main content

Schizophrenia clinical trials at University of California Health

20 in progress, 13 open to eligible people

Showing trials for
  • Adapting and Examining Collaborative Decision Skills Training Among Veterans With Serious Mental Illness

    open to eligible people ages 18 years and up

    Recovery-oriented care is an imperative for the VA, particularly in mental health programming for Veterans with serious mental illness (SMI). Collaborative decision-making (CDM) is a recovery-oriented approach to treatment decision-making that…

    at UCSD

  • Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

    open to eligible people ages 18-65

    Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs…

    at UCLA

  • Brain Stimulation on Cognition, Oscillations and GABA Levels in Schizophrenia

    “Volunteer for paid research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18-47

    People with schizophrenia often have problems with attention, learning and memory and other cognitive abilities that interfere with their work and school performance. Unfortunately, even our best treatments often do not significantly reduce these…

    at UC Davis

  • Enhancing Rehabilitation for Veterans With Serious Mental Illness

    open to eligible people ages 18-75

    This study addresses the critical need for innovative therapeutic interventions in Veterans with serious mental illnesses (SMI) receiving care in VA Psychosocial Rehabilitation and Recovery Centers (PRRCs). The vast majority of individuals with SMI…

    at UCSD

  • Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode

    open to eligible people ages 18-45

    The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training. Half of the patients will also be randomly assigned to the aerobic…

    at UCLA

  • ITEST: Introspective Accuracy As a Novel Target for Functioning in Psychotic Disorders

    open to eligible people ages 18-65

    People with psychotic disorders experience a high level of functional disability, and a major contributor to this disability is introspective accuracy, which is defined as inaccurate judgements of one's abilities and performance on tasks. Yet, no…

    at UCSD

  • Low-dose Buprenorphine As a Modulator of Social Motivation in Schizophrenia

    open to eligible people ages 18-60

    Low social motivation is a significant symptom of schizophrenia and is a major cause of disability and suffering for many patients struggling with the illness. Social motivation refers to the drive to participate in or abstain from social…

    at UCLA

  • Luteolin for the Treatment of People With Schizophrenia

    open to eligible people ages 18-60

    Luteolin is a natural product found in foods such as celery, green pepper, parsley, and chamomile tea. It has been found to have anti-cancer, anti-oxidant, and anti-inflammatory properties. The purpose of this study is to determine if luteolin helps …

    at UCLA

  • Medial-prefrontal Enhancement During Schizophrenia Systems Imaging

    open to eligible people ages 18-64

    This randomized controlled trial in healthy controls (HC) and patients with schizophrenia (SZ) aims to examine 1) the underlying cognitive and neural cause of self-agency deficits in SZ; 2) the responsiveness to a novel navigated repetitive…

    at UCSF

  • Optimizing CBSST with Executive Function Training for Schizophrenia

    open to eligible people ages 60 years and up

    The purpose of this research study to test a blended intervention that combines Executive Function Training with Cognitive-Behavioral Skills Training (E-CBSST). The aims include determining whether E-CBSST is feasible and increases Cognitive…

    at UCSD

  • MDMA in Schizophrenia

    open to eligible people ages 18-60

    Impaired social motivation, or "asociality," is a negative symptom of schizophrenia (SCZ) and a cause of significant functional impairment in the illness. Whereas many symptoms of schizophrenia can be treated with antipsychotic medications, deficits …

    at UCLA

  • AMP SCZ® Observational Study: PREDICT-DPACC

    open to eligible people ages 12-30

    The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) is a large international collaboration to develop algorithms using a set of clinical and cognitive assessments, multi-modal biomarkers, and clinical endpoints that can be used to…

    at UC Irvine UCLA UCSD UCSF

  • Neurophysiologic Biomarkers for Cognitive Rehabilitation

    open to eligible people ages 18-75

    Cognitive symptoms of schizophrenia interfere with daily life-from managing self-care, to more complex tasks like taking medications and living independently. Unfortunately, these cognitive symptoms are not corrected by 'standard of care' treatments …

    at UCSD

  • Brain Stimulation on Higher-Order Cognition

    Sorry, in progress, not accepting new patients

    The purpose of this study is to better understand the neural correlates of higher-order cognition, both in the healthy brain and in schizophrenia, and to determine how these mechanisms are modulated by transcranial direct current stimulation (tDCS)…

    at UC Davis

  • Can Neural Network Instability in Schizophrenia Be Improved with a Very Low Carbohydrate Ketogenic Diet?

    Sorry, in progress, not accepting new patients

    Wide ranging cognitive deficits are major drivers of functional decline and poor outcomes in people with schizophrenia (SZ) and bipolar disorder (BD). Medications do not target pathophysiological mechanisms thought to underlie these deficits. In the …

    at UCSF

  • Enhancing Veteran-Clinical Collaboration in VA PRRCs

    Sorry, not yet accepting patients

    Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives. Although traditional treatments tend to focus on symptom remission,…

    at UCSD

  • Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

    Sorry, in progress, not accepting new patients

    The present study is a confirmatory efficacy trial of Family Focused Therapy for youth at clinical high risk for psychosis (FFT-CHR). This trial is sponsored by seven mature CHR clinical research programs from the North American Prodrome…

    at UCLA UCSD UCSF

  • Obstructive Sleep Apnea Treatment in Serious Mental Illness

    Sorry, not yet accepting patients

    Serious mental illnesses (SMI) like schizophrenia and bipolar disorder are two of the most disabling and costly chronic illnesses worldwide. A high proportion of adults with schizophrenia and bipolar disorder have sleep disorders, like obstructive…

    at UCSD

  • Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia, bipolar I disorder, or autism spectrum disorder (ASD) and to establish the benefit-risk…

    at UCSD

  • Optimizing Cognitive Remediation

    Sorry, in progress, not accepting new patients

    Veterans with mental illness face challenges with community reintegration, including achieving vocational success, attaining their educational goals and going back to school, and maintaining a high quality of life. VA Mental Health Residential…

    at UCSD

Our lead scientists for Schizophrenia research studies include .

Last updated: